SynthesisDiabetes care2023
Global Diabetes Prevalence in COVID-19 Patients and Contribution to COVID-19- Related Severity and Mortality: A Systematic Review and Meta-analysis.
Synthesis in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Prevalence of new-onset diabetes following COVID-19 infection: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Antidiabetic agent use and clinical outcomes in patients with diabetes hospitalized for COVID-19: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- "What Can I Eat?" Healthy Choices for American Indian and Alaska Native Adults With Type 2 Diabetes: Outcomes From a Randomized Waitlist-Controlled Trial of a Diabetes Nutrition Education Program.Journal of nutrition education and behavior · 2025Trial
- Longitudinal Stress Hyperglycemia Trajectories and Severe Outcome in Patients Hospitalized for Viral Respiratory Infections: A 72-Hour Phenotyping Study.Diagnostics (Basel, Switzerland) · 2026Article
- Diabetes Mellitus with Influenza Virus and Subsequent Bacterial Infection: Triple Pathological Interactions and Challenges.International journal of molecular sciences · 2026Review
- Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus.medRxiv : the preprint server for health sciences · 2026Article
- GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.medRxiv : the preprint server for health sciences · 2026Article
- Determinants of COVID-19 and Influenza Vaccination Among People with Diabetes Mellitus in Primary Health Care.Vaccines · 2026Article
- Diabetes Mortality in the Post-Pandemic Era: What Recent Global Burden of Disease Data Reveals About COVID-19's Lasting Impact.Epidemiologia (Basel, Switzerland) · 2026Article
- Early Postural Instability with History of COVID-19 Influence Related to Diabetes: An Exploratory Cross-Sectional Study.Journal of clinical medicine · 2026Article
- An Ecological Study on the Mortality Impact of the COVID-19 Pandemic According to Country Development Status and Pandemic Years.Epidemiologia (Basel, Switzerland) · 2026Article
- Social, psychosocial, and lifestyle determinants of diabetes and prediabetes in US adults before and after COVID-19: a cross-sectional NHANES analysis.Diabetology & metabolic syndrome · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- Clinical Characteristics and Glucocorticoids Efficacy in COVID-19 Patients with Type 2 Diabetes: A Multicenter Retrospective Study.Infection and drug resistance · 2026Article
- Internal factors related to self-management among type 2 diabetes patients during the COVID-19 pandemic as humanitarian emergencies: a scoping review protocol.Systematic reviews · 2025Article
- Health-related quality of life related to diabetes multisensory deficits and derealization.Scientific reports · 2025Article
- Syndemics of Antimicrobial Resistance: Non-communicable Diseases, Social Deprivation, and the Rise of Multidrug-Resistant Infections.Infectious diseases and therapy · 2025Article
- Longitudinal effects of Johnson & Johnson COVID-19 vaccination on metabolic biomarkers in type 2 diabetes mellitus in Ethiopia.World journal of diabetes · 2025Article
- Clinical characteristics and outcomes in patients with diabetes mellitus affected by COVID-19: a retrospective cross-sectional study from a tertiary care center in Pakistan.BMC endocrine disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 and diabetes both contribute to large global disease burdens. PURPOSE: To quantify the prevalence of diabetes in various COVID-19 disease stages and calculate the population attributable fraction (PAF) of diabetes to COVID-19-related severity and mortality. DATA SOURCES: Systematic review identified 729 studies with 29,874,938 COVID-19 patients. STUDY SELECTION: Studies detailed the prevalence of diabetes in subjects with known COVID-19 diagnosis and severity. DATA EXTRACTION: Study information, COVID-19 disease stages, and diabetes prevalence were extracted. DATA SYNTHESIS: The pooled prevalence of diabetes in stratified COVID-19 groups was 14.7% (95% CI 12.5-16.9) among confirmed cases, 10.4% (7.6-13.6) among nonhospitalized cases, 21.4% (20.4-22.5) among hospitalized cases, 11.9% (10.2-13.7) among nonsevere cases, 28.9% (27.0-30.8) among severe cases, and 34.6% (32.8-36.5) among deceased individuals, respectively. Multivariate metaregression analysis explained 53-83% heterogeneity of the pooled prevalence. Based on a modified version of the comparative risk assessment model, we estimated that the overall PAF of diabetes was 9.5% (7.3-11.7) for the presence of severe disease in COVID-19-infected individuals and 16.8% (14.8-18.8) for COVID-19-related deaths. Subgroup analyses demonstrated that countries with high income levels, high health care access and quality index, and low diabetes disease burden had lower PAF of diabetes contributing to COVID-19 severity and death. LIMITATIONS: Most studies had a high risk of bias.
conclusionsThe prevalence of diabetes increases with COVID-19 severity, and diabetes accounts for 9.5% of severe COVID-19 cases and 16.8% of deaths, with disparities according to country income, health care access and quality index, and diabetes disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.